Skip to main content

Cancer prevention and screening

In Europe, 1 man in 3 and 1 woman in 4 will develop cancer before the age of 75. You can reduce and control this risk. So put the odds in your favour!

Dr Jean-Benoît Burrion
Head of Prevention & Screening Clinic

Primary and secondary prevention

  • Nobody is safe from developing cancer. However, you can reduce the risk by 30% by following a few simple rules (primary prevention):
  • Don’t smoke
  • Maintain a healthy weight
  • Eat a balanced diet
  • Get regular exercise
  • Moderate your alcohol consumption
  • Limit your exposure to the sun.

Thanks to screening, certain cancers, including the most common, can be detected at an early stage, even before symptoms appear. Making use of cancer screening is also a way of putting the odds in your favour (secondary prevention).

Prevention and Screening: User Guide

Paragraph body

There are four stages in establishing your risk profile and your personalised prevention plan.

Making an appointment

Begin by making an appointment at the Cancer Prevention and Screening Centre:

Once your appointment has been confirmed, you will receive a questionnaire on your state of health and your lifestyle. You can complete this in complete confidence. It will serve as the basis for your discussion with the doctor when you have your appointment.

Consultation with the doctor

On the day of your appointment, bring your completed questionnaire with you. There is no need to have fasted. It is advisable to arrive 15 minutes beforehand.

You will be seen by a general practitioner specialising in prevention and screening. During your consultation, your risk level will be assessed on the basis of the evaluation questionnaire. Your age, gender, personal and family history, your lifestyle and professional profile will all be taken into account. A full clinical examination will also be carried out.

Medicotechnical examinations

Depending on your risk profile, the doctor may offer additional examinations such as medical imaging, blood analysis, etc.

Specialist consultations

Depending on your risk profile, specialist consultations may also be offered.
For example:

  • Dermatology consultation: to check any skin anomalies (recent change in the size or colour of a mole, for example).
  • Nutritional consultation: to correct an unbalanced diet and/or excess weight by dieting and/or dietary advice.
  • Consultation with the Institut Jules Bordet Smoker Support Centre: we take a medical, pharmacological, psychological and behavioural approach. There are three phases in quitting smoking: preparatory phase, detox phase and consolidation phase.
  • Screening test for osteoporosis: to check your bone capital after the menopause.

Our team

- Dr Jean-Benoît BURRION, Clinical Director

- Dr Françoise ANCIAUX
- Dr Nassim BENGRAB
- Dr Chloé Charline BIETRY-CLAUDET
- Dr Thierry CARBONEZ
- Dr Claire LEFERE
- Dr Evelyne STAQUET
- Dr Daphné T’KINT de ROODENBEKEOncogenetic advice
- Mrs Martine DELMELLE, Oncogenetic advice
Martial BODO, Tabacologie
Hilde VANDECASTEELE, Tabacologie
- Mrs Laurence GILSON, Tabacologie



  • Every month, the Prevention and Screening Clinic welcomes 1st Master student doctors.
  • Cancer epidemiology, prevention and screening courses. Haute École Libre de Bruxelles – Ilya Prigogine.

 Scientific publications

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.

Authors : Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, Tkint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ
Year : 2022
Journal : Prostate Cancer Prostatic Dis
Volume : 25
Pages : 199-207

Implementation of fetal clinical exome sequencing: Comparing prospective and retrospective cohorts.

Authors : Marangoni M, Smits G, Ceysens G, Costa E, Coulon R, Daelemans C, De Coninck C, Derisbourg S, Gajewska K, Garofalo G, Gounongbe C, Guizani M, Holoye A, Houba C, Makhoul J, Norgaard C, Regnard C, Romée S, Soto J, Stagel-Trabbia A, Van Rysselberge M, Vercoutere A, Zaytouni S, Bouri S, DHaene N, DOnle D, Dugauquier C, Racu ML, Rocq L, Segers V, Verocq C, Avni EF, Cassart M, Massez A, Blaumeiser B, Brischoux-Boucher E, Bulk S, De Ravel T, Debray G, Dimitrov B, Janssens S, Keymolen K, Laterre M, van Berkel K, Van Maldergem L, Vandernoot I, Vilain C, Donner C, Tecco L, Thomas D, Désir J, Abramowicz M, Migeotte I
Year : 2022
Journal : Genet Med
Volume : 24
Pages : 344-363

Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the My Personal Breast Screening" (MyPeBS) randomised clinical trial."

Authors : Roux A, Cholerton R, Sicsic J, Moumjid N, French DP, Giorgi Rossi P, Balleyguier C, Guindy M, Gilbert FJ, Burrion JB, Castells X, Ritchie D, Keatley D, Baron C, Delaloge S, de Montgolfier S
Year : 2022
Journal : BMC Cancer
Volume : 22
Pages : 507

Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease.

Authors : Spilleboudt C, de Wilde V, Lewalle P, Cabanne L, Leclerc M, Beckerich F, Bories D, Cardoso S, Soares MP, Vokaer B, Hougardy JM, Flamand V, Racapé J, Abramowicz M, Maury S, Le Moine A
Year : 2021
Journal : Front Immunol
Volume : 11
Pages : 579151

Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks.

Authors : Kehrloesser S, Oberst S, Westerhuis W, Wendler A, Wind A, Blaauwgeers H, Burrion JB, Nagy P, Saeter G, Gustafsson E, De Paoli P, Lovey J, Lombardo C, Philip T, de Valeriola D, Docter M, Boomsma F, Saghatchian M, Svoboda M, Philip I, Monetti F, Hummel H, McVie G, Otter R, Van Harten W
Year : 2021
Journal : Mol Oncol
Volume : 15
Pages : 1277-1288